Formulary
No Formulary Selected

close

 

Select a medication above to begin.

manchurian ginseng

ginseng, Asian (Panax ginseng)

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Entire Monograph

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • ADHD [Insufficient Evidence]
  • aging [Insufficient Evidence]
  • allergic rhinitis [Insufficient Evidence]
  • Alzheimer disease [Insufficient Evidence]
  • androgenic alopecia [Insufficient Evidence]
  • anthracycline-induced cardiotoxicity [Insufficient Evidence]
  • anxiety [Insufficient Evidence]
  • aplastic anemia [Insufficient Evidence]
  • asthma [Insufficient Evidence]
  • athletic performance [Possibly Ineffective]
  • BPH [Insufficient Evidence]
  • breast CA [Insufficient Evidence]
  • bronchitis [Insufficient Evidence]
  • cancer [Insufficient Evidence]
  • cancer-related fatigue [Insufficient Evidence]
  • CHF [Insufficient Evidence]
  • chronic fatigue syndrome [Insufficient Evidence]
  • CKD [Insufficient Evidence]
  • cognitive decline, age-related [Insufficient Evidence]
  • cognitive function [Possibly Effective]
  • cognitive impairment [Insufficient Evidence]
  • common cold [Insufficient Evidence]
  • constipation [Insufficient Evidence]
  • COPD [Insufficient Evidence]
  • depression [Insufficient Evidence]
  • diabetes mellitus [Insufficient Evidence]
  • diabetic neuropathy [Insufficient Evidence]
  • erectile dysfunction [Possibly Effective]
  • exercise-induced muscle damage [Insufficient Evidence]
  • fatigue [Insufficient Evidence]
  • fibromyalgia [Insufficient Evidence]
  • gallbladder disease [Insufficient Evidence]
  • gastritis [Insufficient Evidence]
  • glaucoma [Insufficient Evidence]
  • halitosis [Insufficient Evidence]
  • hangover [Insufficient Evidence]
  • hearing loss [Insufficient Evidence]
  • HIV/AIDS [Insufficient Evidence]
  • HTN [Insufficient Evidence]
  • hyperlipidemia [Insufficient Evidence]
  • impaired glucose tolerance [Insufficient Evidence]
  • inflammatory bowel disease [Insufficient Evidence]
  • influenza [Possibly Effective]
  • insomnia [Insufficient Evidence]
  • liver disease [Insufficient Evidence]
  • male infertility [Insufficient Evidence]
  • menopausal symptoms [Insufficient Evidence]
  • metabolic syndrome [Insufficient Evidence]
  • multiple sclerosis-related fatigue [Possibly Effective]
  • nausea/vomiting [Insufficient Evidence]
  • neuropathic pain [Insufficient Evidence]
  • metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
  • oral CA [Insufficient Evidence]
  • osteoarthritis [Insufficient Evidence]
  • pneumonia [Insufficient Evidence]
  • premature ejaculation [Insufficient Evidence]
  • quality of life [Insufficient Evidence]
  • rheumatoid arthritis [Insufficient Evidence]
  • sexual arousal [Possibly Effective]
  • Sjogren syndrome [Insufficient Evidence]
  • stress [Insufficient Evidence]
  • stroke [Insufficient Evidence]
  • traumatic brain injury [Insufficient Evidence]
  • vascular dementia [Insufficient Evidence]
  • wrinkled skin [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]
Info: extracts generally standardized to 1-80% ginsenoside content

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

allergic rhinitis

[Insufficient Evidence]
Dose: 3 mg/kg/day PO qd

Alzheimer disease

[Insufficient Evidence]
Dose: 4.5-9 g PO qd

androgenic alopecia

[Insufficient Evidence]
Dose: apply 1 mL tonic topically bid

anthracycline-induced cardiotoxicity

[Insufficient Evidence]
Dose: 1 g PO qd; Start: 1st day of chemo

BPH

[Insufficient Evidence]
Dose: 1 g PO qd

breast CA

[Insufficient Evidence]
Dose: 1 g PO qd; Info: used with chemo

bronchitis

[Insufficient Evidence]
Dose: 100 mg PO bid; Info: used with standard tx

cancer

[Insufficient Evidence]
Dose: 3 g PO qd

cancer-related fatigue

[Insufficient Evidence]
Dose: 400 mg PO bid; Alt: 2000 mg PO qd

CHF

[Insufficient Evidence]
Dose: 2 g PO qd; Info: used with or without digoxin

chronic fatigue syndrome

[Insufficient Evidence]
Dose: 100-400 mg PO qd

cognitive function

[Possibly Effective]
Dose: 200-400 mg/day PO divided qd-bid; Alt: 200-960 mg PO x1

cognitive impairment

[Insufficient Evidence]
Dose: 150-450 mg PO qd

common cold

[Insufficient Evidence]
Dose: 200 mg PO qd

constipation

[Insufficient Evidence]
Dose: 20 mL fermented ginseng PO qd given 30min before meals; Info: product containing 25% Korean red ginseng

COPD

[Insufficient Evidence]
Dose: 100-6000 mg PO tid

depression

[Insufficient Evidence]
Dose: 2 g PO qd; Info: used with standard tx

diabetes mellitus

[Insufficient Evidence]
Dose: 2.7 g fermented ginseng PO qd; Alt: 2 g PO tid; 0.2-8 g PO qd

diabetic neuropathy

[Insufficient Evidence]
Dose: 1 g PO qd

erectile dysfunction

[Possibly Effective]
Dose: 700 mg ginseng berry extract PO bid; Alt: 1-2.7 g/day PO divided qd-tid; 150 mg PO q24h

fatigue

[Insufficient Evidence]
Dose: 1 g PO bid; Alt: 80 mg PO qd

fibromyalgia

[Insufficient Evidence]
Dose: 100-400 mg PO qd

glaucoma

[Insufficient Evidence]
Dose: 1 g PO tid

halitosis

[Insufficient Evidence]
Dose: 2.7 g PO qd

hangover

[Insufficient Evidence]
Dose: 100 mL PO x1; Info: drink containing 0.321 mg/mL ginseng extract

hearing loss

[Insufficient Evidence]
Dose: 200 mg PO qd

HTN

[Insufficient Evidence]
Dose: 1.5 g PO tid; Alt: 0.2-8 g PO qd

hyperlipidemia

[Insufficient Evidence]
Dose: 0.2-8 g PO qd

impaired glucose tolerance

[Insufficient Evidence]
Dose: 2.7 g fermented ginseng PO qd; Alt: 50 mg ginseng berry saponins PO tid

influenza

[Possibly Effective]
Dose: 200 mg PO qd; Alt: 1 g PO tid

male infertility

[Insufficient Evidence]
Dose: 200 mg PO qd

multiple sclerosis-related fatigue

[Possibly Effective]
Dose: 250 mg PO bid

menopausal symptoms

[Insufficient Evidence]
Dose: 1 g PO tid; Alt: 500 mg PO 4x/day

metabolic syndrome

[Insufficient Evidence]
Dose: 0.2-8 g PO qd

metabolic dysfunction-associated steatotic liver disease

[Insufficient Evidence]
Dose: 2 g PO qd; Info: used with milk thistle

osteoarthritis

[Insufficient Evidence]
Dose: 1 g PO tid

premature ejaculation

[Insufficient Evidence]
Dose: apply cream topically to glans penis 1h before intercourse

quality of life

[Insufficient Evidence]
Dose: 40 mg PO bid

sexual arousal

[Possibly Effective]
Dose: 3 g PO qd

vascular dementia

[Insufficient Evidence]
Dose: 60 mg PO tid (extract ratio 5:5:1 ginseng:ginkgo:saffron)

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form